Literature DB >> 24049668

Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Moh'd A Salameh1, Evette S Radisky.   

Abstract

Thirty five years ago mesotrypsin was first isolated from the human pancreas. It was described as a minor trypsin isoform with the remarkable property of near total resistance to biological trypsin inhibitors. Another unusual feature of mesotrypsin was discovered later, when it was found that mesotrypsin has defective affinity toward many protein substrates of other trypsins. As the younger sibling of the two major trypsins secreted by the pancreas, cationic and the anionic trypsin, it has been speculated to represent an evolutionary waste with no apparent function. We know now that mesotrypsin is functionally very different from the other trypsins, with novel substrate specificity that hints at distinct physiological functions. Recently, evidence has begun to emerge implicating mesotrypsin in direct involvement in cancer progression. This review will explore the biochemical characteristics of mesotrypsin and structural insights into its specificity, function, and inhibition.

Entities:  

Keywords:  Trypsin; cancer progression; mesotrypsin; protease inhibitors; protein crystallography; serine protease; substrate specificity

Year:  2013        PMID: 24049668      PMCID: PMC3776145     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  77 in total

1.  Genes, cloned cDNAs, and proteins of human trypsinogens and pancreatitis-associated cationic trypsinogen mutations.

Authors:  J M Chen; C Ferec
Journal:  Pancreas       Date:  2000-07       Impact factor: 3.327

2.  On zymogens of human pancreatic juice.

Authors:  C Figarella; F Clemente; O Guy
Journal:  FEBS Lett       Date:  1969-06       Impact factor: 4.124

Review 3.  Protein therapeutics: a summary and pharmacological classification.

Authors:  Benjamin Leader; Quentin J Baca; David E Golan
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

4.  Crystal structure reveals basis for the inhibitor resistance of human brain trypsin.

Authors:  Gergely Katona; Gunnar I Berglund; Janos Hajdu; László Gráf; László Szilágyi
Journal:  J Mol Biol       Date:  2002-02-01       Impact factor: 5.469

5.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues.

Authors:  Xijin Ge; Shogo Yamamoto; Shuichi Tsutsumi; Yutaka Midorikawa; Sigeo Ihara; San Ming Wang; Hiroyuki Aburatani
Journal:  Genomics       Date:  2005-08       Impact factor: 5.736

6.  Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.

Authors:  Moh'd A Salameh; Alexei S Soares; Alexandre Alloy; Evette S Radisky
Journal:  Protein Sci       Date:  2012-06-25       Impact factor: 6.725

7.  Mesotrypsin, a brain trypsin, activates selectively proteinase-activated receptor-1, but not proteinase-activated receptor-2, in rat astrocytes.

Authors:  Yingfei Wang; Weibo Luo; Thomas Wartmann; Walter Halangk; Miklós Sahin-Tóth; Georg Reiser
Journal:  J Neurochem       Date:  2006-08-11       Impact factor: 5.372

8.  Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.

Authors:  C N Nyaruhucha; M Kito; S I Fukuoka
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

9.  Substrate specificity of tissue type plasminogen activator. Characterization of the fibrin independent specificity of t-PA for plasminogen.

Authors:  E L Madison; G S Coombs; D R Corey
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

10.  Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer.

Authors:  Hiroshi Kobayashi; Tatsuo Yagyu; Kiyokazu Inagaki; Toshiharu Kondo; Mika Suzuki; Naohiro Kanayama; Toshihiko Terao
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

View more
  12 in total

1.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

2.  Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation.

Authors:  Vanda Toldi; András Szabó; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2020-02-03       Impact factor: 5.157

3.  Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Authors:  Bonan Lin; Xiaomeng Zhou; Shuye Lin; Xiaoyue Wang; Meiying Zhang; Baoping Cao; Yan Dong; Shuai Yang; Ji Ming Wang; Mingzhou Guo; Jiaqiang Huang
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

4.  Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Authors:  Itay Cohen; Matt Coban; Anat Shahar; Banumathi Sankaran; Alexandra Hockla; Shiran Lacham; Thomas R Caulfield; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

5.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

6.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

7.  Mouse model suggests limited role for human mesotrypsin in pancreatitis.

Authors:  Dóra Mosztbacher; Miklós Sahin-Tóth
Journal:  Pancreatology       Date:  2021-01-22       Impact factor: 3.996

8.  Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.

Authors:  Carmen Ghilardi; Antonietta Silini; Sara Figini; Alessia Anastasia; Monica Lupi; Robert Fruscio; Raffaella Giavazzi; Maria Rosa Bani
Journal:  Oncotarget       Date:  2015-09-29

9.  Protease-activated receptor 2 signaling modulates susceptibility of colonic epithelium to injury through stabilization of YAP in vivo.

Authors:  Longmei He; Yiming Ma; Weiwei Li; Wenxiao Han; Xinhua Zhao; Hongying Wang
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

10.  PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.

Authors:  Honghai Ma; Alexandra Hockla; Christine Mehner; Matt Coban; Niv Papo; Derek C Radisky; Evette S Radisky
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.